FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

86 letters match. Newest first.

  1. Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.

    Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Kellin Chemicals Co., Ltd. - Zhangjiagang

    Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.

    High risk
  4. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  5. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  6. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  7. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  8. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  9. Thrive Health and Wellness, LLC dba Thrive Health Solutions

    FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.

    High risk
  10. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  11. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  12. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  13. MedisourceRx

    MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.

    Medium
  14. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  15. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  16. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  17. Revive Rx LLC dba Revive Rx Pharmacy

    FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.

    High risk
  18. PQ Pharmacy, LLC

    FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.

    High risk
  19. Turbare Manufacturing

    FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.

    High risk
  20. Wells Pharma of Houston, LLC

    FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.

    High risk
  21. Staska Pharmaceuticals, Inc.

    FDA warns Staska Pharmaceuticals, a Nebraska outsourcing facility, that sterile compounded drugs had contamination risks and labeling problems.

    High risk
  22. Kenil Healthcare Private Limited

    FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.

    High risk
  23. AACE Pharmaceuticals, Inc.

    AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.

    High risk
  24. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  25. Tailstorm Health Inc. dba Medivant Health

    Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.

    High risk
  26. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

    High risk
  27. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  28. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  29. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  30. Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

    FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

    High risk
  31. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk
  32. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  33. Evolution Pets LLC

    Evolution Pets marketed SeizureGuard Plus and Life Span Arthritis & Mobility as unapproved drugs for treating dog diseases.

    High risk
  34. Nutrition Strength Ltd.

    FDA warns Nutrition Strength Ltd. over unapproved dog seizure and blood-support supplements marketed as animal drugs.

    High risk
  35. Stokes Healthcare Inc. dba Epicur Pharma

    Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.

    High risk
  36. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  37. BullyKamp Products LLC

    BullyKamp Products LLC marketed unapproved animal drugs with disease-treatment claims on its website, FDA says.

    High risk
  38. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  39. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  40. Northern VA Compounders PLLC, dba Akina Pharmacy

    FDA warns Akina Pharmacy over unsafe production of compounded drugs and sterility risks.

    High risk
  41. Natco Pharma Limited

    FDA warned Natco Pharma of adulterated drugs after finding dirty equipment and weak investigations at an India plant.

    High risk
  42. EzriCare LLC

    EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

    High risk
  43. Delsam Pharma LLC

    Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.

    High risk
  44. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  45. Mei Lan Thailand Co., Ltd.

    Mei Lan Thailand, an API drug manufacturer, refused an FDA inspection and was placed on Import Alert 55-03.

    High risk
  46. Samuel Rodriguez dba KiloKennelzz

    KiloKennelzz marketed Green Monster, an unapproved injectable animal drug, online with claims to treat dog diseases.

    High risk
  47. Curexa – East, LLC dba Curexa

    Curexa - East made compounded drugs under insanitary conditions, with contamination and inadequate cleaning, FDA says.

    High risk
  48. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  49. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  50. TRP Company, Inc

    FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

    High risk